Toinv you pretty much nailed it however... 

1. From what I've seen it will be a challenge to find a BP that does not have drugs that treat one or more of those indications. Apabetalone has shown that it has at least potential in heart, lung, liver kidney, brain and cancer. BP's don't get that BP status without having diverse product lines. It's more likely than not that they would have product sales in areas that would or could be negatively affected if apabetalone is brought to market. Pfizer for example had over 20 drugs, looking alphabetically only from A to M, that could experience negative sales by having apabetalone come to market. I'm not saying it's impossible, it just presents another challenge.

2. You pretty much nailed it.

3. Generally I agree but not totally. Eversana now has a pretty significant investment in RVX so although officially being dormant I get the sense that that's not totally correct. If apabetalone ever has a successful trial that allows Eversana the opportunity to sell this product they will be very handsomely rewarded and they know it. Add a second indication to the mix and it becomes a blockbuster for Eversana.

Not to take anything away from your second point, or anyone else's frustration statements with managements abilities we all have to admit one thing, we are still alive. Most biotechs that have failed, or should I say not passed a number of trials with their drug candidate would have folded up and closed their doors long ago. DM as good or bad as anyone thinks, has kept this thing going for 22 or 23 years now. Not saying that's good or bad, just a fact.

There is only a couple of companies that have a past similar that I've heard of. Immunomedics is one that lived to be sold for over $20 billion. Just a few years before that sale they were trading for just .25 a share. Do we have a chance at that type of success? Chances are slim but not impossible.

I like the science and will keep my position until we flourish or fail.

tada